Clinical Trial Update: RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting not-yet-recruiting status for first-line RC48 (disitamab vedotin) plus AK104 in HER2-overexpressing advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• RC48 (disitamab vedotin)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: NOT_YET_RECRUITING